DACHF yields 4.16% · PFE yields 6.13%● Live data
📍 DACHF pulled ahead of the other in Year 1
Combined, DACHF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DACHF + PFE for your $10,000?
Daicel Corporation engages in the medical/healthcare, smart, safety, materials, engineering plastics, and other businesses in Japan, China, and internationally. The company offers 1,3-Butylene glycol and polyglycerin for cosmetics; chiral and achiral columns/stationary phases, analytical tools, analytical/purification/synthesis/formulation services, chiral and bio reagents, analytical standards, and DNA and RNA-based probes; triacetylcellulose, high performance film, solvent for electronic materials, polymer for resist, semiconductor process cleaning agent, optical parts and lens unit, silver nanoparticle ink, and organic semiconductor devices; and inflators, pyro-fuse, and safety device for non-mobility products; and acetic acid and derivatives, cellulose acetate, acetate tow, cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines. It also provides ceramide derived from konjac root, equol derived from soybeans, ß-cryptoxanthin derived from citrus unshiu, and lactobionic acid derived from milk; DiSPERZiSTA, a dispersible filler for dietary supplement tablet; and MOiSTCARM, a make granules easy to swallow. In addition, the company offers engineering plastics and plastic compound products, high performance polymer, functional sheets, formed trays, and packaging films; water treatment systems and diffusers, such as UF membrane modules, ultra-fine bubble membrane diffusers, and E mizu showers. Its products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and headquartered in Osaka, Japan.
Full DACHF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.